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Abstract
Objectives To analyse predictors for short- and long-term re-
nal function changes after fenestrated and branched
endovascular aortic repair (EVAR).
Methods A total of 157 patients underwent fenestrated and
branched EVAR. Procedural intra-arterial iodinated contrast
volume was documented. Serum creatinine and estimated glo-
merular filtration rate (eGFR) at baseline, during 48 h follow-
ing EVAR, at discharge and latest moment of follow-up were
recorded. Development of post-EVAR acute kidney injury
(AKI; according to AKIN criteria), and potential risk factors
for renal failure were recorded. Multivariate regression analy-
ses were used to identify independent risk factors for AKI and
eGFR decrease during follow-up.
Results Forty-three patients (28 %) developed post-EVAR
AKI. Long procedure time and occlusion of accessory renal
arteries were independent risk factors for development of
AKI. (odds ratio (OR) 1.005 per minute, 95 % CI 1.001–
1.01; p=0.025 and OR 3.02, 95 % CI 1.19–8.16; p=0.029).
Post-EVARAKI was associated with a significantly increased
risk for eGFR decrease at discharge and latest follow-up (haz-
ard ratio (HR) 3.47, 95 % CI 1.63–7.36, p=0.001 and HR
3.01, 95 % CI 1.56–5.80; p=0.001). Iodinated contrast vol-
ume was not an independent risk factor for AKI or eGFR
decrease during follow-up.
Conclusion Development of post-EVAR AKI is an indepen-
dent risk factor for long-term renal function decrease.
Key Points
• Longer procedure time is associated with an increased risk
for AKI.
• Renal perfusion defects on angiography are associated with
increased risk for AKI.
• Post-EVAR AKI is associated with higher probability for
long-term eGFR decrease.
• Iodinated contrast volume is not an independent risk factor
for AKI.
• Iodinated contrast volume is not an independent risk factor
for long-term eGFR decrease.
Keywords Acute kidney injury . Endovascular procedures .
Contrast media . Glomerular filtration rate . Aortic aneurysm
Introduction
Advantages in perioperative survival have led endovascular
aortic repair (EVAR) to become first-line treatment for ana-
tomically suitable aneurysms and complicated acute type B
aortic dissections [1, 2]. Developments in aortic stent grafts
expanded the field of endovascular therapy towards thoraco-
abdominal aneurysms and chronic dissections with insuffi-
cient fixation zone [3, 4]. In order to provide adequate graft
sealing and, at the same time, preserving aortic side branch
patency, the main renal arteries, celiac trunk, superior
* Anna M. Sailer
karmanna@stanford.edu
1 Department of Radiology, Maastricht University Medical Centre,
Maastricht, The Netherlands
2 Department of Radiology, Stanford University Hospitals and Clinics,
Stanford, CA, USA
3 Department of Epidemiology, Maastricht University Medical Centre,
Maatsricht, The Netherlands
4 Department of Vascular Surgery, Cliniques del Europe,
Brussels, Belgium
5 Department of Surgery, Maastricht University Medical Centre,
Maastricht, The Netherlands
Eur Radiol (2016) 26:1613–1619
DOI 10.1007/s00330-015-3993-8
mesenteric artery and/or supra-aortic vessel are catheterized
and stented via fenestrations or branches in the aortic main
device. Over the last few years, fenestrated and branched
EVAR procedures have increasingly been performed. Ongo-
ing innovations in devices provide endovascular solutions for
more and more challenging anatomy and pathology. The
worldwide demographic shift and decreasing indications for
open (surgical) aortic repair further contribute to this develop-
ment.With endovascular procedure complexity, the amount of
intra-arterial administered iodinated contrast media increases
substantially. At the same time, new techniques like fusion
image road-mapping and robotic navigation have been ap-
plied and are under further development to reduce procedural
iodinated contrast volume and accelerate complex EVAR pro-
cedures [5, 6]. For proper risk analysis and adequate proce-
dure management, knowledge of predictors of renal function
following complex EVAR is required. Despite numerous re-
search in the field of iodinated contrast, the effect of currently
used low-osmolar intra-arterial applied iodinated contrast on
short-term and long-term renal function decrease remains un-
clear [7]. Several studies on renal outcome after endovascular
aortic repair have been published, but these studies lack ad-
justments for contrast volume and other factors by a multivar-
iate risk factor analysis for renal outcome [8–10].
The aim of this study was to evaluate predictors for short-
and long-term renal function changes after complex fenestrat-
ed and branched endovascular aortic repair, with particular
focus on risk factors for AKI and the effect of AKI on long
term-renal damage.
Materials and methods
This retrospective study was approved by the institutional
review board; written informed consent was waived. Serum
creatinine (SCr) levels and estimated glomerular filtration rate
(eGFR) changes were retrospectively evaluated in 157 con-
secutive patients who underwent fenestrated and/or branched
endovascular aortic repair for juxta-, suprarenal and
thoracoabdominal aortic aneurysms between January 2006
and March 2014 at our institution. All procedures were per-
formed under general anaesthesia. Procedural intra-arterial io-
dinated contrast volume (iaIC, low-osmolar, 300 mg iodine/
ml) and procedure time were documented. SCr levels at base-
line, during 48 h following the intervention, at discharge as
well as during follow-up were retrieved from the electronic
medical patient records. Corresponding eGFR levels were cal-
culated using the Modification of Diet in Renal Disease for-
mula [11]. Patient characteristics, including age, sex, presence
of diabetes and congestive heart failure, were retrieved from
the medical records. Procedure-related death was recorded.
Procedure-related loss of renal parenchyma was assessed by
reviewing procedural angiograms together with pre- and post-
procedure CT: angiographically apparent perfusion defects by
intentional stent graft coverage of accessory renal arteries as
well as iatrogenic renal artery injuries with occlusion of renal
artery branches during the EVAR procedures were recorded.
Furthermore it was assessed whether the patients received
additional iodinated contrast media during computed tomog-
raphy angiography (CTA) within 48 h following the EVAR
procedure.
Assessment of post-EVAR acute kidney injury (AKI)
Post-EVAR AKI was defined by comparing the individual
post-EVAR SCr measurements to preoperative baseline SCr
measurements. According to the definition of the Acute Kid-
ney Injury Network criteria of AKI, patients with (1) an abso-
lute SCr increase of at least 0.3 mg/dl and/or (2) a relative
increase of at least 50 % above baseline within 48 h following
the complex EVAR procedures qualified to have post-EVAR
AKI [12].
Decrease in eGFR during follow-up
The primary endpoint was decrease in eGFR at discharge. At
baseline, discharge and latest moment of follow-up patients
were grouped according to their eGFR into five categories: (1)
eGFR < 15ml/min/1.73 m2, (2) eGFR 15–29ml/min/1.73 m2,
(3) eGFR 30–44 ml/min/1.73 m2, (4) eGFR 45–59 ml/min/
1.73 m2 and (5) eGFR ≥ 60 ml/min/1.73 m2. Decrease in
eGFR was defined as a transition to a category with lower
eGFR when compared to baseline. Secondary endpoint was
decrease in eGFR at latest moment of follow-up.
Statistical analysis
For descriptive purposes, categorical variables were presented
as absolute numbers and percentages. Continuous variables
were presented as a mean±standard deviations (if normally
distributed) or as a median with a range (if not normally dis-
tributed). For development of AKI, the effects of risk factors
were analysed using multivariate logistic regression. For
eGFR decrease at discharge of last follow-up, data were
analysed with time-to-event analysis to account for differ-
ences in follow-up between patients. Multivariable Cox re-
gression analyses were used for calculation of hazard ratios
with corresponding 95 % confidence intervals. The hazard
ratios represent the independent effect of predefined risk fac-
tors on the probability of an event. Observations were cen-
sored at occurrence of an event (eGFR decrease) or at the end
of follow-up. Patients with transient eGFR decrease, with
eGFR decrease by one category at discharge but recovery to
the eGFR category at baseline, were considered as event-free
at the end of follow-up. Predefined risk factors considered
relevant as potential predictors were age, sex, baseline eGFR,
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administered contrast volume, presence or absence of AKI,
additional administration of iodinated contrast within 48 h
post EVAR, renal artery branch occlusion, diabetes and con-
gestive heart failure. P values less than 0.05 were considered
to indicate statistical significance. Analyses were performed
with SPSS statistics 20.0, Chicago, Illinois.
Results
The study group consisted of 131 men and 26 women with a
mean age of 73±6 years. The distribution of baseline charac-
teristics is presented in Table 1. Median stay until discharge
was 6 days (range 2–61 days, interquartile range (IQR) 3–9)
and median time until last follow-up was 380 days (range 16–
2762 days, IQR 117–925). One patient died perioperatively
and this patient was excluded from the analysis because no
data were accessible for post-EVAR renal function. Another
nine patients died within 30 days (range 3–28 days) after the
intervention as a result of procedure-related complications.
Seven of those nine patients (78 %) developed post-EVAR
AKI. Among the other 146 patients, 36 patients (24 %) devel-
oped post-EVAR AKI. In total, 43 of 156 patients (28 %)
developed post-EVAR AKI. Mean procedural iaIC volume
was 162±77 ml (range 50–450 ml). Mean procedural iaIC
volume in patients who developed post-EVAR AKI was 195
±88 ml (range 50–350 ml) versus 149±69 ml (range 65–
450 ml) in patients without post-EVARAKI (p=0.001). Mean
procedure time in patients who developed post-EVAR AKI
was 282±138 min (range 119–603 min) versus 197±89 min
(range 69–395 min) in patients without post-EVAR AKI (p=
0.001). In 26 patients (17 %), procedure-related loss of renal
parenchyma was apparent.
The results of the logistic regression analysis evaluating the
independent contribution of factors for the development of
post-EVAR AKI are shown in Table 2. Development of AKI
was significantly associated with procedure time (odds ratio
(OR) per minute 1.005, 95 % CI 1.001–1.01, p=0.001) and
renal artery branch occlusion (OR 3.02, 95 % CI 1.12–8.16,
p=0.029). Although iodinated contrast volume was signifi-
cantly higher in patients with AKI in the univariate analysis
(Table 1), iodinated contrast volume was no longer an inde-
pendent risk factor for post-EVAR AKI after adjustment for
other factors in the multivariate analysis.
Table 3 shows the results from the Cox proportional hazard
model to assess the independent effects of predefined risk
factors on probability of eGFR decrease at discharge. At dis-
charge, the number of patients with eGFR decrease by at least
one category was 37. Development of post-EVAR AKI was
associated with a significantly increased risk for eGFR de-
crease at discharge (hazard ratio (HR) 3.47, 95 % CI 1.63–
7.36; p=0.001). Non-significantly but slightly increased haz-
ard ratios were observed for accessory renal artery occlusion,
iodinated contrast volume, age, male gender and patients with
diabetes (p>0.05).
Table 4 shows the results for long-term eGFR decrease. At
the moment of last follow-up, the number of patients with
eGFR decrease by at least one category was 51. Patients with
Table 1 Baseline characteristics of the entire patient population (n=157) and distribution between patients with (n=43) and without AKI (n=113)
All patients AKI No AKI
Mean Std.
deviation






Age (years) 73 6 73 68 77 72 6 73 6 0.801
Baseline eGFR (ml/min/1.73 m2) 63 18 63 49 78 64 18 61 19 0.263
Baseline serum creatinine (μmol/l) 106 37 97 84 119 104 36 110 38 0.116
Intra-arterial contrast volume (ml) 162 77 150 100 200 149 69 195 88 0.001
Procedure time (min) 220 110 196 140 276 282 138 197 89 0.001
BMI (kg/m2) 26 4 26 24 28 26 4 26 4 0.710
Male gender (n) 131 26 79 % 86 % 0.303
Congestive heart failure (n) 15 142 12 % 9 % 0.599
Hypertension (n) 82 75 56 % 51 % 0.616
Hyperlipidaemia (n) 109 48 72 % 69 % 0.846
Diabetes (n) 13 144 9 % 8 % 0.787
CT angiography within 48 h post EVAR
(n)
51 106 21 % 18 % 0.731
Accessory renal artery coverage/renal
artery branch occlusion, with perfu-
sion defect (n)
26 131 31 % 14 % 0.02
25p 25th percentile, 75p 75th percentile
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post-EVAR AKI had a significantly increased probability of
eGFR decrease at last follow-up (HR 3.01, 95 % CI 1.56–
5.80, p=0.001). Procedure time, iodinated contrast volume
and other patient characteristics were not significantly associ-
ated with long-term eGFR decrease.
Figure 1 shows the distribution of eGFR categories in all
patients over time. Figure 2 illustrates the mean eGFR mea-
surements over time, for subgroups with and without AKI and
renal artery occlusions, respectively. Both groups start at sim-
ilar baseline mean eGFR. For patients with AKI, eGFR levels
decrease sharply during 48 h following complex EVAR and
show substantial recovery at discharge. At the end of follow-
up eGFR levels are substantially lower than at baseline for
patients who developed AKI, whereas patients without AKI
show only minor decrease in mean eGFR levels at the end of
follow-up when compared with baseline.
Discussion
This study presents a retrospective evaluation of renal
function changes after intra-arterial administration of
high volumes of low-osmolar iodinated contrast media
in a large patient population. Well-documented pre- and
post-interventional renal function testing and thorough
follow-up allowed us to evaluate the renal function in
the postoperative period as well as beyond discharge of
the patients. In multivariate regression analyses, several
risk factors were evaluated regarding their association
with postoperative renal function decrease. We discuss
the most important findings with respect to the design
of the study and current literature.
Influence of intra-arterial iodinated contrast
and procedure time on short- and long-term renal
function
For postoperative renal function decrease, which we term
‘post-EVAR AKI’ throughout the manuscript, we used the
definition from the Acute Kidney Injury Network (AKIN) to
assess post-EVAR AKI in order to provide a commonly used
definition of AKI in research and clinical practice [13–16].
Another definition of contrast material-induced nephropathy
(CIN) uses SCr increase of at least 0.5 mg/dl and/or at least
25 % above baseline within 72 h post intervention [17, 18].
When applying the CIN criteria for AKI, the patient group
who developed post-EVAR AKI would have been the same
in our study, excluding two patients that were not included
when applying the AKIN criteria. AKIN criteria were used
in our study for two main reasons: (1) we followed a recently
Table 3 Cox regression analysis
for various risk factors for eGFR
decrease by at least one category
at time of hospital discharge after
complex EVAR
Hazard ratio 95 % CI P value
Age (per life-year) 1.012 0.945–1.083 0.74
Sex 1.169 0.423–3.233 0.763
Diabetes 1.938 0.679–5.529 0.216
Congestive heart failure 0.935 0.265–3.306 0.917
Baseline eGFR (per ml/min/1.73 m2) 0.996 0.977–1.016 0.722
Iodinated contrast volume (per ml) 1.002 0.996–1.008 0.58
CTAwithin 48 h post EVAR 1.216 0.506–2.219 0.662
Renal artery occlusion 1.97 0.866–4.481 0.106
Acute kidney injury 3.467 1.633–7.360 0.001
Procedure time (min) 0.997 0.993–1.002 0.204
Table 2 Logistic regression
analysis for various risk factors
for AKI within 48 h after complex
EVAR
Odds ratio 95 % CI P value
Age (per life-year) 1.04 0.960–1.127 0.334
Sex 1.357 0.415–4.432 0.613
Diabetes 1.674 0.425–6.599 0.426
Congestive heart failure 1.51 0.364–6.270 0.571
Baseline eGFR (per ml/min/1.73 m2) 0.993 0.969–1.018 0.605
Iodinated contrast volume (per ml) 1.003 0.997–1.009 0.323
CTAwithin 48 h post EVAR 1.514 0.532–4.310 0.437
Renal artery occlusion 3.021 1.118–8.163 0.029
Procedure time (min) 1.005 1.001–1.010 0.025
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advocated recommendation from the American College of
Radiology in order to standardize the various used definitions
of CIN [19] and (2) post-EVAR AKI might not be due to
contrast medium but might predominantly be influenced by
other factors rather than low-osmolar contrast volume [7].
With respect to the long-lasting discussion on the toxicity of
iodinated contrast material [7, 20, 21], we made two observa-
tions: First iodinated contrast volume was associated with a
slightly increased risk for every millilitre of contrast applied;
however, it was not an independent risk factor for AKI and
long-term renal function decrease post EVAR in complex an-
eurysms. Although univariate analysis suggested a significant
effect of contrast volume for the development of AKI, this
effect disappeared after adjustment for procedure time. This
finding corroborates the hypothesis that high contrast volume
is a marker for complexity of the procedure and that patients
undergoing more complex procedures have higher risk for
renal function decrease. One has to be aware that in any ret-
rospective study, observed associations are not to be confused
with causative relationships. Although we found a strong as-
sociation between procedure time and short-term renal func-
tion decrease, a causal relationship for procedure time itself is
hereby not proven. Second, it has been questioned whether
post-interventional decrease in renal function is more likely a
transient subclinical [22, 23] or even artificial [24, 25] short-
term phenomenon, or indeed a relevant predictor for long-
term renal dysfunction. When looking at the mid- and long-
term renal function measurements we made an interesting
observation. While presence of AKI was a significant predic-
tor for eGFR decrease at discharge and last follow-up, the data
provide no evidence that procedure time or other factors were
significantly associated with eGFR decrease beyond 48 h. Al-
though no significant associations were found with the other
risk factors, directions of the hazards ratios conform with ex-
pectations for older age, diabetes and baseline eGFR. Lack of
statistical significance may be due to the limited sample size.
Accessory renal artery coverage
Accessory renal artery coverage and other iatrogenic renal
artery side branch occlusion with consecutive visible paren-
chymal perfusion defect on angiogram or follow-up CTAwas
a significant predictor for eGFR decrease in the immediate
postoperative period. Any new parenchymal perfusion defect
identifiable on angiogram or CTA therefore is an indicator for
short-term decrease of renal function. At discharge and latest
follow-up, this risk factor was still associated with increased
risk of eGFR decrease (HR=1.970 and HR=1.371, respec-
tively) but this association was no longer statistically signifi-
cant (p=0.106 and p=0.384, respectively). This finding is in
line with the results from a non-randomized retrospective
study, where no significant long-term renal deterioration was
found in patients with accessory renal artery coverage during
EVAR compared to a control group [26]. In the long-term,
function of the focal parenchymal mass loss seems to be main-
tained by the remaining renal tissue. In our study, 28 cases of
accessory renal artery coverage or renal artery side branch
injuries occurred, of which only two cases did not show any
apparent parenchymal infarction on angiographic imaging and
therefore were not included in this category. Beyond registra-
tion of infarction, no attempt was made to further quantify the
diameter of the occluded renal arteries and the volume of the
renal tissue defect. In accordance with a Society of Vascular
Surgery consensus statement on the treatment of abdominal
Fig. 1 Percentage of patients per eGFR category at baseline, during 48 h
following EVAR, at discharge and latest follow-up (FU)
Table 4 Cox regression analysis
for various risk factors for eGFR
decrease by at least one category
at latest moment of follow-up
after complex EVAR
Hazard ratio 95 % CI P value
Age (per life-year) 1.02 0.964–1.079 0.5
Sex 0.858 0.393–1.872 0.7
Diabetes 1.113 0.372–3.327 0.56
Congestive heart failure 0.431 0.119–1.562 0.23
Baseline eGFR (per ml/min/1.73 m2) 0.995 0.978–1.013 0.616
Iodinated contrast volume (per ml) 1 0.996–1.005 0.868
CTAwithin 48 h post EVAR 1.125 0.527–2.402 0.761
Renal artery occlusion 1.371 0.774–2.790 0.384
Acute kidney injury 3.013 1.563–5.808 0.001
Procedure time (min) 1.001 0.997–1.004 0.707
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aortic aneurysms [27], at our institution only accessory arter-
ies smaller than or equal to 3 mm in diameter and supporting
not more than one-third of the renal parenchyma are regularly
overstented. This approach seems a relatively safe method at
least for the long-term renal function. For larger accessory
renal arteries, we cannot infer definite conclusions from our
data, and any attempt to preserve their flow (e.g. with addi-
tional fenestrations) might be favourable.
In conclusion, intra-arterial iodinated contrast volume is
not an independent risk factor for development of short- or
long-term renal function decrease after endovascular repair of
complex aortic aneurysms. Patients who develop post-EVAR
AKI are at significant higher risk for long-term renal function
decrease.
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